The catalyst calendar for the next six months is narrow but consequential. DOM reports on a semi-annual cadence and does not issue quarterly financial prints, so the tape between now and the H1 2026 results is driven by an AGM vote, a consensus-reset trading update, and — crucially — the first H1 supply-chain EBITDA print under the new CEO. The market is not looking for a beat; it is looking for evidence that the margin slide ended at FY25.
No Results
The July interim is the binary. Management trimmed FY25 EBITDA guidance to £130–140m in August 2025 and delivered £133.9m — acceptable, but the quality of that miss was ugly because supply-chain EBITDA (70-75% of group profit) fell £10m on a 0.9% order-count decline. Net debt to EBITDA has climbed from 1.21x to 1.99x (the board's own covenant is 2.5x) and RBC has already cut its target to 285p on 15 April with a Q1 miss warning. A second consecutive H1 SCC EBITDA decline in July would push leverage through 2.0x and, credibly, force a buyback pause — and the buyback is the load-bearing pillar of the current equity story.
The quieter catalyst nobody is modelling: the 2027 Master Franchise Agreement with DPZ. The current royalty is capped at 3.0%; every specialist flagged this as the single largest unresolved binary, but there is no disclosure schedule and no signal yet. An FY26 update on renewal terms — in either direction — would reprice the stock more than any operating line.
**The stock is priced for a broken franchisor, and the franchisor is intact.** EV/EBITDA of 8.3x is the lowest in 26 years — below the 2008-09 GFC trough and roughly 45% below the 10-year median of 15.5x. FCF conversion remains 111% of net income over the last five years and ROCE, even at a cycle low, is still 24.9%. The 30-year history shows every time the multiple has compressed this hard, reversion has come — the question is timing, not direction.
**Capital-return math works at a mid-teens shareholder yield.** Dividend yield is 6.4% on an 11.3p payout, FCF covers it 1.8x, a £20m buyback is running, and £500m has been returned since March 2021 — share count down 23% in a decade. Of fourteen material promises made since 2020, cash-return promises are the ones management has delivered cleanly across three CEOs. You get paid to wait.
**Activist pressure from Browning West is de-risking capital allocation for you.** A 5%-plus shareholder (Usman Nabi, ex-DOM board member) publicly demanded a £100m buyback and the end of the second-brand hunt — and by March 2026 the second-brand programme was formally cancelled, £6m of transaction costs written off, and the CEO who championed it was gone. A governance system that needs an activist is not ideal, but if you are a minority shareholder, that activist is working for you.
**The moat in the specific category is genuinely widening.** UK pizza-takeaway share hit 52.6% in FY25 as Pizza Hut UK closed 68 stores and Papa John's UK closed 70-plus — a textbook duopoly-to-monopoly consolidation. More than 80% of franchisees are contractually locked into DPG supply, 99.9% distribution reliability, and four-SCC national scale that no competitor can economically replicate. The bear framing calls pizza commoditised; the share data says otherwise inside pizza.
**The tape is the first piece of evidence in nine months that the sellers are done.** RSI swung from 24 to 64 in three weeks, MACD histogram flipped positive on 2 April, and 30-day realized vol halved from the 64% August 2025 panic peak. Price is testing the falling 200-day at 192p — if it holds as pivot rather than ceiling, the January 2025 death cross is the last bearish anchor still in place.
**Supply-chain EBITDA — 70-75% of group profit — is in a volume-levered down-cycle nobody has modelled bottoming.** SCC EBITDA as a percentage of system sales went from 8.7% in FY24 to 7.9% in FY25 on a mere 0.9% order decline. The commissary's operating leverage cuts both ways; SCC5 Avonmouth adds depreciation ahead of system-sales growth. What breaks the thesis: an H1 2026 print with SCC EBITDA flat or down — leverage through 2.0x, buyback pause, re-rating to a UK-consumer multiple not a franchisor one.
**The 2027 MFA renewal is a one-way door and the first signal lands in 2026.** If DPZ extracts 50-100bps of additional royalty, roughly £8-16m of EBITDA leaves the business permanently; if development-incentive terms harden, the 2,000-store target becomes unfundable. There is no public signal yet, and DPZ's own US comps were -0.5% in Q1 2025 — a negotiating posture that rewards toughness. This is the largest unquantified binary in the file.
**Five CEOs in six years is not a cycle — it is a pattern.** Ex-CEO Andrew Rennie held only 15,000 shares (10.9% of salary, versus the 200% policy) when he was removed, and his 2028/2033 store targets were set less than two years before being quietly shelved. Nicola Frampton is a clean operator but has never been a public-company CEO. Confirmation of the concern: a sixth CEO change by FY27, or failure to reaffirm any multi-year quantified target at the May AGM or July interims.
**Franchisee unit economics are being taxed before your eyes.** April 2024's 10% minimum-wage rise plus October 2024's NI hike dropped FY25 store openings to 31, barely half the 60 per year the 2028 target required. The Employment Rights Bill (autumn 2026) adds sick-pay, zero-hours and day-one dismissal rights; the Karshan Irish Supreme Court ruling already forced a £10.4m Shorecal impairment from the same regulatory family. If UK regulators follow Ireland on driver classification, every franchisee P&L resets — and DPG's supply-chain volumes go with them.
**The "growth pivot" just failed, publicly.** The chicken category is a £3bn market where DPG holds 3.8% share, introduced in November 2025 as the new growth pillar by a CEO who was gone eleven days later. Frampton's March 2026 framing — "focusing on the core" with no numeric long-range target — is honest retrenchment but also an admission that the 2023 Rennie playbook is dead without a successor. A compounder without a credible growth algebra is just a utility yielding 6.4%.
This is a close call with a slight edge to the bears, and the deciding weight is the supply-chain cycle, not the valuation. The For side is right that the franchisor is intact, the yield is real, and the activist floor under capital discipline is working for minority shareholders — but none of those points answers why someone should own the name before the July interim, when a second consecutive SCC EBITDA decline would validate the bear structural-margin read and push leverage into buyback-pause territory. I would wait. The data point that flips the view is one clean H1 2026 print: supply-chain EBITDA flat or better on system-sales LFL that is positive on orders, not just ticket. If that prints, the 8.3x multiple is genuinely a trough and the patient money wins; if it does not, the 2027 MFA starts being negotiated from a position of weakness and the valuation gap to DPZ and DMP stays wider for longer than any buyback can offset. Cheap is not the same as attractive yet.